{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:25:43Z","timestamp":1787775943380,"version":"build-2784847793"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>\n                    Despite numerous reports on the procoagulant activities of G-CSF, the effect of plerixafor on the hemostatic system is not clearly understood. This study aims to evaluate the effects of plerixafor on the hemostatic system when used for autologous stem cell mobilization (ASCM) for poor mobilizers (PM) with lymphoma and multiple myeloma. Patients who were performed ASCM with plerixafor in combination with GCSF were prospectively enrolled. Cohort A included patients mobilized with G-CSF whereas Cohort B included patients mobilized with G-CSF + plerixafor. Blood samples were obtained before the mobilization regimen and just before apheresis. CBC, coagulation tests, CRP, protein C and S, vWF antigen, and factors VIII and XII were studied. Cohort A (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 30) of which 9 received chemotherapy + G-CSF. Factor VIII, INR, vWF antigen, and CRP significantly increased after G-CSF compared to baseline. Decreases in protein C and S were significant (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    &lt;0.001;\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    =0.005). In cohort B (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    =15) no significant changes were observed in coagulation parameters Factor levels, protein C and S before and after the plerixafor. Fibrinogen decreased slightly after plerixafor administration (4.2773\u00b12.2125 vs. 3.6987\u00b11.5062;\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    =0.02). remained unchanged. In conclusion the addition of plerixafor to G-CSF did not exert further significant procoagulant effects.\n                  <\/jats:p>","DOI":"10.4103\/hemoncstem.hemoncstem-d-24-00006","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T03:00:27Z","timestamp":1737342027000},"page":"211-218","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["The effects of plerixafor on the hemostatic system in patients undergoing stem cell mobilization"],"prefix":"10.4103","volume":"17","author":[{"given":"\u00d6zge","family":"Ko\u00e7","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Ankara University School of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"Do\u011fan","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Ankara University School of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U\u011fur","family":"\u015eahin","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation Unit, Medicana International Ankara Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekin","family":"Kircali","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara University School of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Koyun","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara University School of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutlu","family":"Arat","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation Unit, Florence Nightingale Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhit","family":"\u00d6zcan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara University School of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"issue":"(4)","key":"R1-20250123","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bbmt.2009.11.012","article-title":"Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation","volume":"16","author":"Wuchter","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"(28)","key":"R2-20250123","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","article-title":"Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin\u2019s lymphoma","volume":"27","author":"DiPersio","year":"2009","journal-title":"J Clin Oncol"},{"issue":"(23)","key":"R3-20250123","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"issue":"(4)","key":"R4-20250123","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000354132","article-title":"Physiology and pharmacology of plerixafor","volume":"40","author":"Fricker","year":"2013","journal-title":"Transfus Med Hemother"},{"issue":"(2)","key":"R5-20250123","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/sj.bmt.1704341","article-title":"Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors","volume":"33","author":"Topcuoglu","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"(6)","key":"R6-20250123","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1177\/1076029608320720","article-title":"Effects of rhG-CSF plus dexamethasone on hemostatic parameters in healthy granulocyte donors: role of u-PA and nitric oxide","volume":"15","author":"Ekmekci","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"issue":"(4)","key":"R7-20250123","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1089\/15258160260194820","article-title":"Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors","volume":"11","author":"Canales","year":"2002","journal-title":"J Hematother Stem Cell Res"},{"issue":"(4)","key":"R8-20250123","first-page":"559","article-title":"Plasma level of stromal derived factor-1 (SDF-1) is increased in disseminated intravascular coagulation patients who have poor outcomes: in vitro effect of SDF-1 on coagulopathy","volume":"120","author":"Kim","year":"2007","journal-title":"Thromb Res"},{"issue":"(2)","key":"R9-20250123","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3324\/haematol.2012.071456","article-title":"Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial","volume":"98","author":"Russell","year":"2013","journal-title":"Haematologica"},{"issue":"(5)","key":"R10-20250123","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/01.ATV.21.5.731","article-title":"Elevated factor VIII levels and the risk of thrombosis","volume":"21","author":"Kamphuisen","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"(2)","key":"R11-20250123","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0008-6363(97)00039-4","article-title":"von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?","volume":"34","author":"Lip","year":"1997","journal-title":"Cardiovasc Res"},{"issue":"(2)","key":"R12-20250123","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.1995.tb05143.x","article-title":"A reliable marker of endothelial cell dysfunction: does it exist?","volume":"90","author":"Blann","year":"1995","journal-title":"Br J Haematol"},{"issue":"(6206)","key":"R13-20250123","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/337471a0","article-title":"Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate","volume":"337","author":"Bussolino","year":"1989","journal-title":"Nature"},{"issue":"(8)","key":"R14-20250123","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/sj.leu.2404271","article-title":"Blood oxidative status and selectins plasma levels in healthy donors receiving granulocyte-colony stimulating factor","volume":"20","author":"Cella","year":"2006","journal-title":"Leukemia"},{"issue":"(4)","key":"R15-20250123","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0925-5710(96)00459-8","article-title":"Effects of granulocyte colony-stimulating factor on the hemostatic system in healthy volunteers","volume":"63","author":"Kuroiwa","year":"1996","journal-title":"Int J Hematol"},{"issue":"(4)","key":"R16-20250123","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.tmrv.2008.05.005","article-title":"Granulocyte colony-stimulating factor administration: adverse events","volume":"22","author":"D\u2019Souza","year":"2008","journal-title":"Transfus Med Rev"},{"issue":"(2)","key":"R17-20250123","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bbmt.2011.07.014","article-title":"Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma","volume":"18","author":"Attolico","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"(9)","key":"R18-20250123","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","article-title":"Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation","volume":"14","author":"Pusic","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R19-20250123","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2016.05.028","article-title":"Plerixafor improves the endothelial health balance. The effect of diabetes analysed by polychromatic flow cytometry","volume":"251","author":"Cappellari","year":"2016","journal-title":"Atherosclerosis"},{"issue":"(10)","key":"R20-20250123","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/cyto.a.22109","article-title":"Type 2 diabetes mellitus impairs the maturation of endothelial progenitor cells and increases the number of circulating endothelial cells in peripheral blood","volume":"81","author":"Lombardo","year":"2012","journal-title":"Cytometry A"},{"key":"R21-20250123","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/blood.V130.Suppl_1.963.963","article-title":"Studies of white cell, platelet, and coagulation activation with plerixafor administration in patients with sickle cell disease","volume":"130","author":"Petra","year":"2017","journal-title":"Blood"},{"issue":"(11)","key":"R22-20250123","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/sj.bmt.1701481","article-title":"Analysis of rhG-CSF-effects on platelets by in vitro bleeding test and transcranial Doppler ultrasound examination","volume":"22","author":"S\u00f6hngen","year":"1998","journal-title":"Bone Marrow Transplantation"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.HEMONCSTEM-D-24-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:46:24Z","timestamp":1787773584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.HEMONCSTEM-D-24-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/hemoncstem.hemoncstem-d-24-00006","relation":{},"ISSN":["1658-3876","2589-0646"],"issn-type":[{"value":"1658-3876","type":"print"},{"value":"2589-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2024-01-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}